Poxel Reports its 2025 Revenue and Provides an Update on its Financial PositionFeb 16, 2026 1:02 PM Eastern Standard Time# Poxel Reports its 2025 Revenue and Provides an Update on its Financial PositionShare---- As at 31 December 2025, cash and cash equivalents amounted to €0.9 million.- Poxel generated revenue of €5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales- Gross sales of TWYMEEG® in Japan continued to accelerate, increasing by 15.0% in the fourth qu ...

Company Overview - Pee Safe, founded in 2013, focuses on affordable sanitary solutions and body-friendly products aimed at reducing health and wellness complications for women [5] - The product lineup includes organic cotton tampons, breast pads, panty liners, intimate wash products, wipes, maternity care products, and anti-pollution dust masks [5] - Pee Safe competes with brands such as Sirona, Sanfe, Nua Women, Plush, and major companies like Johnson & Johnson and Procter & Gamble [5] Recent Funding - Pee Safe has secured $32 million (approximately INR 288 crore) in its Series C funding round from OrbiMed, which is backed by Netmeds, through a mix of primary and secondary share sales [3][4] - The investment will be utilized to expand its offline retail presence, enhance brand-led marketing, and accelerate growth in quick commerce and leading marketplaces [3][4] Strategic Goals - The fresh capital will significantly deepen Pee Safe's offline distribution and accelerate momentum in quick commerce and e-commerce, allowing the company to reach more consumers at scale [4] - OrbiMed's Dr. Sunny Sharma and Sumona Chakraborty will join Pee Safe's board as part of the investment deal [4] Industry Insights - The global femtech market was valued at $60.2 billion in 2024 and is projected to grow at a CAGR of 16% over the next decade, indicating strong demand for sanitary and hygienic products [6] - The femtech segment is attracting significant investment due to the high demand for sanitary and hygienic products in the consumer industry [6]

Core Insights - Electra Therapeutics has successfully raised $183 million in Series C financing to support its pivotal trial for a rare disease candidate [1] Group 1: Financing Details - The Series C financing was co-led by Nextech and EQT Life Sciences, with participation from notable investors including Sanofi, Mubadala Capital, OrbiMed, Blue Owl Capital, and RA Capital Management [1]

Core Insights - AirStrip, a US-based healthcare technology company, has secured a $50 million growth credit facility and additional equity funding from OrbiMed to accelerate its growth strategy [1][4] - The funding will support the company's expansion in clinical surveillance, patient monitoring, alarm management, and decision support, addressing the rising demand for its offerings [1][2] Funding Utilization - The credit facility will be used to advance product innovation, expand go-to-market initiatives, and enable rapid deployment across hospitals and healthcare systems nationwide [2] - AirStrip currently collaborates with over 675 hospitals in the US, providing clinicians with secure access to near real-time clinical data via the internet and mobile devices [2][3] Market Expansion - With the new funding, AirStrip aims to expand into the broader hospital market of over 6,000 facilities, focusing on customer implementation, product development, and workforce growth [3] - The company's product portfolio includes continuous, mobile-enabled monitoring across various care settings, with clinical decision support solutions that transform fragmented data into actionable insights [3] Leadership Statements - AirStrip's CEO emphasized that the funding will enhance how clinicians access and act on critical clinical information, improving decision-making and patient safety [4] - OrbiMed's general partner highlighted AirStrip's potential and their excitement to support the company's next phase of growth and innovation [4]

Group 1 - On September 5, 2023, Heng Rui Medicine announced an exclusive licensing agreement with Braveheart Bio for its self-developed cardiac myosin small molecule inhibitor HRS-1893, granting Braveheart Bio rights to develop, produce, and commercialize HRS-1893 globally, excluding Greater China [1] - Braveheart Bio will pay a total of $75 million to Heng Rui Medicine, which includes a $65 million upfront payment (comprising $32.5 million in cash and $32.5 million in Braveheart Bio equity) and a $10 million milestone payment upon completion of technology transfer [1] - Heng Rui Medicine could receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties [1] Group 2 - Braveheart Bio was established in 2024 in Delaware, USA, with major investors including Forbion Capital and OrbiMed, both of which are influential in the life sciences investment sector [2] - The partnership with top-tier life sciences investment institutions highlights Heng Rui Medicine's international competitiveness and accelerates the global development of innovative therapies in the cardiovascular field [2] - HRS-1893 is a significant innovation in Heng Rui Medicine's cardiovascular portfolio, currently in Phase III clinical trials, with over 10 innovative products in clinical research stages targeting cardiovascular diseases [3] Group 3 - Heng Rui Medicine emphasizes a dual approach of independent research and open collaboration to enhance its global innovation footprint, actively exploring partnerships with multinational pharmaceutical companies, innovative startups, and leading regional pharmaceutical firms [3]

Core Viewpoint - Heng Rui Medicine has entered into an exclusive licensing agreement with Braveheart Bio for its self-developed cardiac drug HRS-1893, which is currently in Phase III clinical trials, utilizing the "NewCo" model to expand internationally [1][2]. Group 1: Licensing Agreement Details - The agreement allows Braveheart Bio to develop, produce, and commercialize HRS-1893 globally, excluding China, with Heng Rui receiving a total of $75 million upfront, including $32.5 million in cash and $32.5 million in equity [1]. - Heng Rui is also entitled to receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties, bringing the total potential value of the agreement to $1.088 billion [1]. Group 2: Product Information - HRS-1893 is a highly selective Myosin small molecule inhibitor that normalizes myocardial contractility, reduces left ventricular hypertrophy, and improves diastolic compliance [2]. - The drug has undergone multiple clinical trials, with Phase I data recently presented at the 2025 European Society of Cardiology (ESC) Congress, and Phase III trials for obstructive hypertrophic cardiomyopathy have been initiated in China [2]. Group 3: Company Strategy and Performance - Heng Rui Medicine emphasizes a dual approach of independent research and open collaboration, aiming to strengthen international partnerships to enhance the efficient translation of research outcomes into the global drug innovation network [2]. - The company has completed a total of 16 licensing agreements to date, contributing nearly 2 billion yuan in revenue from licensing transactions in the first half of the year [3].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $12.7 million, a significant increase from $5.2 million in Q2 2024, primarily driven by an $8 million milestone payment from Torii and net YCANT revenue of $4.5 million [22][24] - GAAP net income for Q2 2025 was $200,000 or $0.02 per share, compared to a net loss of $17.2 million or $3.7 per share in Q2 2024 [24] - Non-GAAP net income for Q2 2025 was $2.4 million or $0.25 per share, compared to a net loss of $14.4 million or $3.11 per share in Q2 2024 [24][26] Business Line Data and Key Metrics Changes - The YCANT business reported a record 13,434 dispensed applicator units in Q2 2025, representing a sequential growth of 32.8% over the prior quarter [6][22] - Net YCANT revenue in Q2 2025 was $4.5 million, reflecting shipments to distribution partners, offset by standard gross to net adjustments [22][23] Market Data and Key Metrics Changes - The company is experiencing strong demand for YCANT, particularly in territories with high prevalence of molluscum contagiosum and robust medical and pharmacy benefit coverage [8][12] - Over 1.6 million patients in Japan contract molluscum annually, representing a significant market opportunity for YCANT [19] Company Strategy and Development Direction - The company is focused on expanding its commercial strategy for YCANT, targeting high-value territories and enhancing relationships with healthcare professionals [10][12] - An amended agreement with Torii Pharmaceutical is expected to provide up to $18 million in non-dilutive capital in 2025, strengthening the company's balance sheet [14][15] - The company plans to initiate a global Phase III program for YCANT for the treatment of common warts, with the first patient expected to be dosed in the U.S. in 2025 [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in generating strong and sustainable growth driven by YCANT's unique product attributes and the relationships built with the medical community [28] - The company anticipates continued growth in the second half of 2025, supported by the ongoing expansion of its sales force and improved access to YCANT [28][44] Other Important Information - The company executed a reverse stock split at a ratio of one for ten shares, impacting the share price [24] - As of June 30, 2025, the company had cash and cash equivalents of $15.4 million, which may not be sufficient to fund operations for the next year without additional capital [26] Q&A Session Summary Question: Expansion of the sales force and reasons for increased YCANT adoption - Management expects to add 5 to 10 more sales representatives in the near term, attributing success to the tenacity of sales reps and strong support from the medical community [32][34] Question: Growth expectations for Q3 and patient access updates - Management noted that molluscum is often diagnosed year-round, and they are seeing increased adoption among pediatricians and dermatologists [43][44] Question: Increase in receivables and gross to net (GTN) changes - The increase in receivables is partly due to collection terms of sixty days, and management has not changed the WACC since launch [47][51]

Core Insights - Myriad Genetics has secured a five-year senior secured term loan credit facility of up to $200 million from OrbiMed, which includes $125 million of funded capital and an option to borrow an additional $75 million until June 30, 2027 [1][2] - The facility matures on July 31, 2030, and has an interest rate based on the one-month secured overnight financing rate (SOFR) plus 6.50%, with a SOFR floor of 2.50% [1] - The new credit facility replaces Myriad's previous asset-based lending (ABL) facility and is secured by substantially all the assets of Myriad Genetics and its subsidiaries [2] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3] - The company aims to improve patient care and reduce healthcare costs through its diagnostic tests [3] Partner Overview - OrbiMed is a prominent healthcare investment firm with over $17 billion in assets under management, investing globally across the healthcare industry [4] - The firm provides tailored financing solutions and extensive resources to support the growth of healthcare companies [4]

Core Insights - Verrica Pharmaceuticals reported a sequential quarterly growth of 32.8% in Q2 2025, with 13,434 YCANTH dispensed applicator units, indicating strong demand for the product [1][2] - The company received an $8 million milestone payment from Torii Pharmaceutical for the initiation of a global Phase 3 program for common warts [1][2] Company Performance - The growth in dispensed applicator units reflects the effectiveness of Verrica's focused commercial strategy, leading to increased prescriptions from dermatology and pediatric practices [2] - The company attributes its growth to a robust patient access strategy, strong reimbursement, and an extensive distribution network [2] Product Information - YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum, a contagious skin disease affecting approximately six million people in the U.S., primarily children [3][4] - The product is delivered via a single-use applicator, allowing for precise dosing and targeted administration [3] Financial Developments - The company has amended its Credit Agreement with OrbiMed and has a collaboration agreement with Torii Pharmaceutical, which includes potential additional milestone payments [2] - Approximately 225 million lives are eligible for YCANTH coverage, with commercially insured patients paying only $25 per treatment visit [3] Future Outlook - Verrica is looking forward to updates on its development strategy for VP-315, aimed at treating basal cell carcinoma [2][4]

Core Viewpoint - Aadi Bioscience, Inc. has successfully closed a private placement, raising approximately $100 million to support its oncology therapeutics initiatives and operational funding [1][3]. Group 1: Private Placement Details - Aadi sold a total of 21,592,000 shares of common stock at a price of $2.40 per share and issued pre-funded warrants for 20,076,500 shares at a price of $2.3999 per share [2]. - The private placement was led by Ally Bridge Group, with participation from new investors such as OrbiMed, Invus, and Kalehua Capital, as well as existing investors including Avoro Capital, KVP Capital, and Acuta Capital Partners [1][2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized for upfront payments under a license agreement with WuXi Biologics and for general working capital [3]. - The combined proceeds from this private placement and the sale of Aadi's FYARRO® business, along with existing cash and marketable securities, are expected to fund operations into 2028, including anticipated clinical data readouts for its ADC portfolio [3]. Group 3: Regulatory Information - The shares sold in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without registration or an applicable exemption [4]. - Aadi has entered into a registration rights agreement to file a registration statement with the SEC for the resale of the shares sold in the private placement [4].